media – Page 49 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

What is the impact of the House of Representatives’ passage of the draft biosafety law amid the controversy on WuXi

On September 9, the House of Representatives of the United States Congress returned from a summer break and immediately scheduled a series of legislative votes, including the draft Biosafety Act (H.R. 8333). The draft biosecurity law passed the House of Representatives with 306 votes in favor and 81 votes against, but the 70% support rate made it the most divisive draft bill in the same batch, and even narrowly fell below the “bottom line” of more than two-thirds of the votes to pass the bill. The draft Biosafety Act places five companies, including WuXi AppTec and WuXi Biologics, on the list of “biotechnology companies of concern” on the grounds of “national security”, and intends to restrict the use of funds, loans or subsidies from the United States government to cooperate with these companies. Unlike previous committees that voted in small groups, this time there were several members of the House ...
- Source: drugdu
- 84
- October 6, 2024
The old mechanism of “using drugs to support doctors” has been broken

Recently, the State Council Information Office held a series of press conferences on “Promoting High-quality Development”. The leadership of the National Health Commission answered many questions in the field of domestic medicine and health at the meeting. When introducing the basic situation, Lei Haichao, director of the National Health Commission, said that the National Health Commission adheres to the public welfare and works with relevant departments to deepen the medical reform. Over the past decade, especially since the 18th National Congress of the Communist Party of China, the old operating mechanism of using drugs to support doctors and consumables to support doctors has been historically broken, and a new operating mechanism dominated by medical services has been initially established. The income of public medical institutions has changed from the original three channels to two channels of government financial subsidies and medical service charges. “The old mechanism of relying on ...
- Source: drugdu
- 151
- October 5, 2024
sell right, sell well, and sell for a long time

First, the essence of business is market competition, and the market is the battlefield. Business people should have a sales mindset, and salespeople need to have a business perspective. There is a view that sales and business are different positions in pharmaceutical companies, with different responsibilities and assessment standards, and it is difficult to integrate the two positions, so you can focus on your own duties. However, the performance appraisal of most pharmaceutical companies is still stuck in the “butt determines the head” standard, and there is rarely a global vision of “the head decides the butt”. It is beneficial for sales and business to empathize, but it cannot completely resolve all conflicts and disputes. At the time of the transformation of the pharmaceutical industry, cross-disciplinary talents who are both proficient in sales and business are increasingly becoming valuable resources for enterprises to compete for. The business position in the ...
- Source: drugdu
- 94
- October 5, 2024
Digital therapeutics are a big failure

The digital therapeutics industry has evolved and evolved beyond all expectations. In June 2021, Pear Therapeutics, the “first stock of digital therapeutics”, was listed; In April 2023, he filed for bankruptcy and bankruptcy; A year later, Better Therapeutics, another star digital therapeutics company, also fell; Four months ago, Akili chose to sell himself and delist and go private. So far, the three musketeers of overseas digital therapeutics have all fallen. If you count from the listing of Pear, a three-year cycle, the waves will sweep away the heroes. On the surface, the main reason for the collapse of these companies is financial problems, but the deeper reason is the commercialization challenges faced by digital therapeutics. The challenge is that digital therapeutics need to have drug-like efficacy in order to gain market acceptance, but the embarrassment is that prescription digital therapeutics are not drugs per se, but more about using technical ...
- Source: drugdu
- 75
- October 5, 2024
The China Securities Regulatory Commission encourages cross-border mergers and acquisitions of unprofitable assets, and a new path for Biotech to land in the capital market?

Wu Qing, chairman of the China Securities Regulatory Commission, said at a press conference of the State Council that in order to further stimulate the vitality of the M&A and restructuring market, the CSRC has studied and formulated the “Opinions on Deepening the Reform of the M&A and Restructuring Market of Listed Companies” (“M&A Six”, hereinafter referred to as the “Opinions”), including supporting the transformation and upgrading of listed companies in the direction of new quality productivity, encouraging industrial integration, improving regulatory tolerance, and improving the transaction efficiency of the restructuring market. Among them, it is clear that it will vigorously support listed companies to carry out cross-industry mergers and acquisitions and acquisitions of unprofitable assets based on transformation and upgrading. This means that unprofitable biotech companies may usher in a new path to land in the capital market. At the meeting, Wu Qing said that mergers and acquisitions are ...
- Source: drugdu
- 102
- October 5, 2024
Medtronic, new progress in ECMO

On September 26, Medtronic’s official website announced the launch of a new ECMO system called VitalFlow™. This is a configurable single-system ECMO solution built on simplicity and performance. According to the official website, the VitalFlow system has a large, intuitive touch screen that centrally displays real-time performance data, provides configurability, and uses the proven Medtronic Nautilus™ ECMO oxygenator design to achieve long-term stable performance. Medtronic said that the VitalFlow™ ECMO system bridges the gap between bedside care and in-hospital transportation, providing clinicians with an easier and smarter ECMO experience. Dr. Karim Bandali, president of the cardiac surgery business within the Medtronic cardiovascular product portfolio, believes that the VitalFlow system is simple and easy to use, allowing users with different comfort levels to serve patients confidently and efficiently. It can be easily moved between different departments of the hospital and has durable and reliable performance. In March 2024, Medtronic completed ...
- Source: https://mp.weixin.qq.com
- 148
- October 4, 2024
【EXPERT Q&A】What documents are needed for drug import declaration? Why?

Drugdu.com expert’s response: The requirements for documents in drug import customs clearance are complex and comprehensive, aiming to ensure the quality, safety, and legality of imported drugs in compliance with China’s drug administration regulations. Ⅰ. Key Documents Import Drug Registration Certificate (or Pharmaceutical Product Registration Certificate) Reason: Verifies that the drug has been registered in China and approved by relevant national departments, allowing for legal sale and use domestically. Drug Business License or Drug Production License and Enterprise Legal Person Business License Reason: Demonstrates that the enterprise importing drugs possesses the legal qualifications for drug operation or production, as well as the legitimacy and scope of business. Certificate of Origin Reason: Proves the origin of the imported drugs, serving as an important basis for customs import administration and tariff collection. Purchase Contract Reason: Verifies the authenticity and legality of the transaction for imported drugs, including information on buyer and seller, transaction quantity, price, etc. Packing List, ...
- Source: drugdu
- 92
- October 4, 2024
To build China’s own blood brand

In recent years, China’s blood gas analyzer market has shown a strong development trend, especially in critical illness, emergency and surgical scenarios, and the scale has expanded dramatically. At present, the market size of blood gas analysis in China is about 2.7 billion yuan, and the industry growth rate is about 20%. From the perspective of market share, imported brands have the first-mover advantage in R&D and market, according to the data reported by the China Research Institute of Puhua Industry Research Institute, about 80% of the current market share of the domestic blood gas analyzer market is still occupied by imported brands, mainly for Radiometer, Wolfen, Abbott, etc., and domestic brands are mainly represented by the head brand of blood gas. According to the statistics of the bidding network, in the first half of 2024, the scale and demand for blood gas equipment procurement across the country ...
- Source: https://mp.weixin.qq.com
- 131
- October 4, 2024
KIMES BUSAN

Organiser：E&EX Exhibition Company, Korea Time：October 18 – 20, 2024 Address：55 Apec-ro, Haeundae-gu, Busan, 612-704, South Korea Exhibition hall：Busan Exhibition & Convention Center Product range: Medical Equipment: Medical technology equipment, consumables, medical electronic devices, ophthalmic equipment & protective products, surgical instruments, emergency response equipment, hospital, dental, & medical facilities, dental service equipment & disposable medical products, hospital & household disposable medical products, hospital dentistry, medical data processing systems, dental plastic surgery, rehabilitation equipment, etc. In Vitro Diagnostics & Clinical Laboratory Equipment: Endoscopy systems, B-mode ultrasound, examination equipment, ENT treatment instruments, dynamic analysis instruments, total laboratory solutions, clinical diagnostic equipment, diagnostic reagents, precision medicine, POCT (Point-of-Care Testing) home diagnostic devices, clinical laboratory equipment. Rehabilitation & Nursing Supplies: Orthopedic devices, walkers, hearing aids, audio guide systems for visually impaired, manual wheelchairs, electric wheelchairs, crutches, walking aids, massagers, healthcare apparel, fitness equipment, training machines, wrist & ankle braces, wearable neck braces, back braces, ...
- Source: drugdu
- 121
- October 3, 2024
Optimization strategy for production process of RNA targeted drugs

RNA targeted drugs are a completely new category of drugs that are completely different from small molecule drugs and antibody drugs. On the one hand, they can target mRNA, ncRNA, and other intracellular proteins through gene silencing to inhibit their expression and achieve the goal of treating diseases; On the other hand, new generation vaccines and protein replacement therapies can also be developed based on mRNA. RNA targeted drugs are undoubtedly a strategic frontier in biopharmaceutical innovation, with broad potential application scenarios in the future. The production process technology of mRNA industrialization is particularly important for the widespread application and industrialization of mRNA. Based on this, this article will focus on the optimization strategies for the production process of RNA targeted drugs. Stability chemical modification enhances drug safety and efficacy For RNA targeted drugs, chemical modification (excluding tissue targeting ligands) mainly has two basic functions: firstly, chemical modification can significantly ...
- Source: drugdu
- 142
- October 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.